Abstract | BACKGROUND: METHODS: RESULTS:
Arthralgia and skin manifestations resolved in all patients. Proteinuria normalized in three patients and stabilized in all but one of the others. Steroids were indefinitely stopped in six patients (35%) and reduced to around 40% of the basal dosage in the other patients. During belimumab therapy, three extrarenal and one renal SLE flares were diagnosed accounting for a rate of renal flares of 0.02/patient/year. No major adverse events leading to therapy withdrawal occurred. CLINICAL CASE: CONCLUSIONS:
|
Authors | Valentina Binda, Barbara Trezzi, Nicoletta Del Papa, Lorenzo Beretta, Giulia Frontini, Giulia Porata, Paolo Fabbrini, Maria Rosa Pozzi, Piergiorgio Messa, Renato Alberto Sinico, Gabriella Moroni |
Journal | Journal of nephrology
(J Nephrol)
Vol. 33
Issue 5
Pg. 1019-1025
(Oct 2020)
ISSN: 1724-6059 [Electronic] Italy |
PMID | 32002799
(Publication Type: Journal Article)
|
Chemical References |
- Antibodies, Monoclonal, Humanized
- Glucocorticoids
- Immunosuppressive Agents
- belimumab
|
Topics |
- Antibodies, Monoclonal, Humanized
- Female
- Glucocorticoids
(adverse effects)
- Humans
- Immunosuppressive Agents
(adverse effects)
- Lupus Erythematosus, Systemic
(diagnosis, drug therapy)
- Lupus Nephritis
(drug therapy)
- Renal Dialysis
- Treatment Outcome
|